The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer (NCT01270399) | Meir Medical Center | 2011-01-01 |
Track The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined. automatically
Every clearance here is in the API, with alerts when new ones post.